$tr2['classname']

肺癌

$tr2['classname']

乳腺癌

$tr2['classname']

结直肠癌

$tr2['classname']

前列腺癌

$tr2['classname']

甲状腺癌

$tr2['classname']

宫颈癌

$tr2['classname']

胃癌

$tr2['classname']

肝癌

$tr2['classname']

胆囊癌

$tr2['classname']

卵巢癌

$tr2['classname']

食管癌

$tr2['classname']

胰腺癌

$tr2['classname']

膀胱癌

$tr2['classname']

淋巴瘤

$tr2['classname']

子宫内膜癌

$tr2['classname']

肾癌

$tr2['classname']

罕见肿瘤

首页 > TAG信息列表 > Repotrectinib

瑞普替尼|最新研究

再鼎医药公布Repotrectinib治疗ROS1阳性非小细胞肺癌全球1/2期TR
对多个靶点有效的洛普替尼 I/II 期TRIDENT-1临床试验中显示出前
ROS1阳性NSCLC患者有效率高达57%，Repotrectinib（TPX-0005，洛普替尼）2